[Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
OBJECTIVE
The breast cancer and the prostate cancer are considered as the most frequently occurred metastatic tumors in bones. The bone pain appears in majority of patients with metastases. One possibility how to reduce or to remove this pain is the administration of the radiotherapy to the place of metastases. The present medicine disposes of two ways how to administer radiotherapy in the place of metastases: externally irradiation (loco-regional or half-body) or intravenous administration of bone-seeking therapeutic radiopharmaceuticals.


METHODS
We introduced intravenous administration of 153Samarium-EDTMP in 57 patients (30 prostate cancer, 23 breast cancer, 4 renal cell carcinoma). Mean applied activity was 40 MBq per kg of patient's body weight.


RESULTS
After 153Sm-EDTMP administration we observed pain relief of various degree in 75% of patients for three months. 1 and 3 months after 153Samarium-EDTMP administration the following haematologic parameters changes were seen: a) 7% reduction in red cell count in one month after administration, 15% reduction after three months. b) 43% reduction in leukocyte count in one month after administration, 24% reduction after three months. c) 50% reduction in platelet count in one month after administration, 23% reduction after three months. In all three haematological profiles (red cells, leukocytes, platelets) we detected reduction of values after treatment with 153Samarium-EDTMP. This reduction culminates one month after administration and in three months leukocytes and platelets count was getting better.


CONCLUSIONS
Myelosuppression was mild and temporary. No patients had grade 4 hematological toxicity and only three patients (5%) had grade 3 hematological toxicity (National Cancer Institute Common Toxicity Criteria).
Oddelĕní nukleární medicíny Fakultní nemocnice, Hradec Králové.
J
J
Dolezal
J
J
Vizd'a
E
E
Cermáková
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001853:Bone Marrow / Q000187:drug effects*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care; D010198:Pancytopenia / Q000209:etiology; D011471:Prostatic Neoplasms / Q000473:pathology; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D012493:Samarium / Q000009:adverse effects / Q000627:therapeutic use*
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D019275:Radiopharmaceuticals; D012493:Samarium; C061972:samarium Sm-153 lexidronam